Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden

We examined the impact of spatial, temporal, histologic, and quantitative factors on concordance between TP53 alterations in tissue DNA vs in circulating tumor DNA (ctDNA). Four hundred and thirty‐three patients underwent next‐generation sequencing (NGS) in which both tissue and blood samples were e...

Full description

Bibliographic Details
Main Authors: Cheyennedra C. Bieg‐Bourne, Ryosuke Okamura, Razelle Kurzrock
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Molecular Oncology
Subjects:
Online Access:https://doi.org/10.1002/1878-0261.12672
id doaj-318382a4daed48129937195569c685ef
record_format Article
spelling doaj-318382a4daed48129937195569c685ef2020-11-25T03:43:35ZengWileyMolecular Oncology1574-78911878-02612020-06-011461242125110.1002/1878-0261.12672Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burdenCheyennedra C. Bieg‐Bourne0Ryosuke Okamura1Razelle Kurzrock2Center for Personalized Cancer Therapy Moores Cancer Center University of California San Diego La Jolla CA USACenter for Personalized Cancer Therapy Moores Cancer Center University of California San Diego La Jolla CA USACenter for Personalized Cancer Therapy Moores Cancer Center University of California San Diego La Jolla CA USAWe examined the impact of spatial, temporal, histologic, and quantitative factors on concordance between TP53 alterations in tissue DNA vs in circulating tumor DNA (ctDNA). Four hundred and thirty‐three patients underwent next‐generation sequencing (NGS) in which both tissue and blood samples were evaluated. TP53 was detected in 258 of 433 patients (59.6%); 215 had tissue TP53 alterations (49.7%); 159, ctDNA (36.7%); and 116, both tissue and ctDNA (27.8%). Overall concordance rate between ctDNA and tissue biopsies for TP53 alterations was 67.2%; positive concordance was 45.0%. Overall concordance for TP53 did not vary among patients with ≤ 2 months vs > 6 months between test samples; however, positive concordance trended higher when time intervals between test samples were shorter, suggesting that the lack of difference in overall concordance may be due to the large number of negative/negative tests. There was a trend toward higher overall concordance based on biopsy site (metastatic vs primary) (P = 0.07) and significantly higher positive concordance if the tissue biopsy site was a metastatic lesion (P = 0.03). Positive concordance significantly decreased in noncolorectal cancer patients vs colorectal cancer patients (P = 0.02). Finally, higher %ctDNA was associated with higher concordance rates between blood and tissue (P < 0.001). Taken together, these data indicate that both blood and tissue DNA sequencing are necessary to evaluate the full scope of TP53 alterations, and that concordance rates may be related to multiple factors including, but not limited to, amount of ctDNA, histologic context, and site of tissue biopsy.https://doi.org/10.1002/1878-0261.12672cancerconcordancectDNAgenomicsTP53
collection DOAJ
language English
format Article
sources DOAJ
author Cheyennedra C. Bieg‐Bourne
Ryosuke Okamura
Razelle Kurzrock
spellingShingle Cheyennedra C. Bieg‐Bourne
Ryosuke Okamura
Razelle Kurzrock
Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
Molecular Oncology
cancer
concordance
ctDNA
genomics
TP53
author_facet Cheyennedra C. Bieg‐Bourne
Ryosuke Okamura
Razelle Kurzrock
author_sort Cheyennedra C. Bieg‐Bourne
title Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
title_short Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
title_full Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
title_fullStr Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
title_full_unstemmed Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
title_sort concordance between tp53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor dna burden
publisher Wiley
series Molecular Oncology
issn 1574-7891
1878-0261
publishDate 2020-06-01
description We examined the impact of spatial, temporal, histologic, and quantitative factors on concordance between TP53 alterations in tissue DNA vs in circulating tumor DNA (ctDNA). Four hundred and thirty‐three patients underwent next‐generation sequencing (NGS) in which both tissue and blood samples were evaluated. TP53 was detected in 258 of 433 patients (59.6%); 215 had tissue TP53 alterations (49.7%); 159, ctDNA (36.7%); and 116, both tissue and ctDNA (27.8%). Overall concordance rate between ctDNA and tissue biopsies for TP53 alterations was 67.2%; positive concordance was 45.0%. Overall concordance for TP53 did not vary among patients with ≤ 2 months vs > 6 months between test samples; however, positive concordance trended higher when time intervals between test samples were shorter, suggesting that the lack of difference in overall concordance may be due to the large number of negative/negative tests. There was a trend toward higher overall concordance based on biopsy site (metastatic vs primary) (P = 0.07) and significantly higher positive concordance if the tissue biopsy site was a metastatic lesion (P = 0.03). Positive concordance significantly decreased in noncolorectal cancer patients vs colorectal cancer patients (P = 0.02). Finally, higher %ctDNA was associated with higher concordance rates between blood and tissue (P < 0.001). Taken together, these data indicate that both blood and tissue DNA sequencing are necessary to evaluate the full scope of TP53 alterations, and that concordance rates may be related to multiple factors including, but not limited to, amount of ctDNA, histologic context, and site of tissue biopsy.
topic cancer
concordance
ctDNA
genomics
TP53
url https://doi.org/10.1002/1878-0261.12672
work_keys_str_mv AT cheyennedracbiegbourne concordancebetweentp53alterationsinbloodandtissueimpactoftimeintervalbiopsysitecancertypeandcirculatingtumordnaburden
AT ryosukeokamura concordancebetweentp53alterationsinbloodandtissueimpactoftimeintervalbiopsysitecancertypeandcirculatingtumordnaburden
AT razellekurzrock concordancebetweentp53alterationsinbloodandtissueimpactoftimeintervalbiopsysitecancertypeandcirculatingtumordnaburden
_version_ 1724518959196143616